lead position
Trademarks
From seller vetting and proprietary screening technology to brand collaboration and industry partnerships, Temu explains how its intellectual property enforcement programme combats infringement on its marketplace
August 10, 2026
Features list
-
Jim Brogan, Brian Eutermoser and Janna Fischer discuss the ways that the unsuccessful IPR petitioner at the Patent Trial and Appeal Board still can challenge validity in subsequent district court litigation -
IP owners are constantly looking for new countries in which to protect and enforce their rights, particularly as growth in mature markets slows. Three countries that are opening up to international investment are Cuba, Iran and Myanmar. Natalie Rahhal and James Nurton find out about the latest developments in these three states, particularly for trade mark owners, and also look at other jurisdictions that could become more important for IP
-
The latest article in our series by the MARQUES IP Outer Borders Team looks at the localism trend and its implications for brands. By Kate Swaine, Mary Jane Lemenchick, Laetitia Lagarde and Thomas Raab
-
Jorge Vega, Eduardo Castañeda and Guillermo González of Basham Ringe and Correa explain how the Trans-Pacific Partnership would affect Mexico’s IP system
-
Héctor Chagoya and Claudia Campos of Becerril Coca & Becerril discuss the features of the Mexican patent system under a new environment for human creativity recognition, and analyse statutory provisions given the scarcity of administrative or judiciary precedents available for interpreting Mexican law
-
Laura Collada and Ariadna Galvez of Dumont Bergman Bider & Co discuss Mexico’s experience of the Madrid System since 2013 and point out some flaws in its new opposition system
Local Insights
Sponsored by
Inspicos
Peter Koefoed of Inspicos examines how the EPO Enlarged Board of Appeal referral G 1/26 could clarify the application of G 1/24 when assessing the allowability of amended patent claims under the EPC
Sponsored by
Maiwald
Alexander Ortlieb, Moritz Kampmann, and Stephan Maidl of Maiwald highlight six EPO appeal decisions that map the absolute floor of what patent applications for AI inventions must disclose – and how spectacularly some applicants miss that mark
Sponsored by
Inventa
Vítor Palmela Fidalgo of Inventa reviews three years of Unified Patent Court jurisprudence, examining emerging approaches to claim interpretation, prosecution history, doctrine of equivalents, and prior use
Sponsored by
Bird & Bird
The singer is among an increasing number of celebrities using trademark law to counter AI-generated impersonation. Ann Henry, Sarah McMullen, and Isabel Humburg of Bird & Bird (Ireland) examine evolving challenges for brand owners
Sponsored by
Inspicos
Nils Byg Jørgensen of Inspicos says a recent EPO decision addresses the extent to which the description and drawings shall be consulted when interpreting claims under European Patent Convention provisions other than patentability
Sponsored by
Inspicos
Jakob Pade Frederiksen of Inspicos provides a status update on the pending case in the lead-up to oral proceedings before the EPO Enlarged Board of Appeal on May 8 2026
Sponsored by
Bird & Bird
Anna Wolters-Höhne of Bird & Bird summarises proposed updates regarding market access activities and explains the practical implications for patentees and potential defendants, with reference to recent Unified Patent Court case law
Sponsored by
NLO
Emily Flood and Gamze Gezer-Voerknecht of NLO examine how European patent law applies to the booming nutraceuticals market, focusing on EPO practice, therapeutic versus non‑therapeutic claims, and strategic drafting considerations
Sponsored by
Patrinos & Kilimiris
Maria Kilimiris of Patrinos & Kilimiris explains a recent decision regarding how genuine use is assessed for trademarks registered across broad categories of goods and their subcategories
Sponsored by
Bird & Bird
Annika Lückemann and Jan van Dieck of Bird & Bird analyse the Unified Patent Court’s opening ruling concerning a supplementary protection certificate, highlighting procedural peculiarities, urgency considerations, and possible implications for pharmaceutical originator-generic disputes